Pharmacogenomics

Pharmacogenomics: From Bench to Bedside (Part 2)
CME (AMA PRA Category 1 Credits™) 1.5; ACPE (UAN:0853-9999-17-047-L01-P) 1.5

Sunday, October 8
8:00 AM - 9:45 AM

Pharmacogenomics (PGx), the study of how one’s genes may affect an individual’s response to medication, has reached the translational stage for various specialties in medicine. Over thirty years of research has led to promising advances in the clinical practice. This conference provides the background, resources and practical application examples to implement pharmacogenomics and make a difference in patient lives. Mayo Clinic experts, with experience leading the implementation of PGx, will provide practical guidance on a range of topics, background and research including: when to order testing, drug/gene selection, informatics, and case study working sessions.

Sunday, October 8th, 2017
8:00 am Welcome and Review
Pharmacogenomics: From Bench to Bedside Part II
• Outline example institutional resources and clinical tools to assist in developing and/or implementing pharmacogenomic services.

• Identify examples of the use of genome data-rich model systems and genome-wide techniques to gain insight into mechanisms responsible for variation in response to drug therapy.

• Describe the major barriers to the routine implementation of pharmacogenomics across practice sites

8:15 am 1.Systems & Tools for Implementation
Wayne (Nick) T. Nicholson, M.D., Pharm.D., R.Ph.
8:55 am Q&A
9:05 am 2.Research in Pharmacogenomics
Leiwei Wang, M.D., Ph.D.
9:35 am Q&A
9:45 am Break
Clinical Case Applications in Pharmacogenomics Part II
• Define the role of pharmacogenomics testing in cardiovascular drug response.
• Utilize genetics to minimize adverse events and maximize drug efficacy.
• Understand the limitation of pharmacogenomics testing in practice of cardiovascular disease
• Provide examples of how pharmacogenomic testing can be utilized prescribing medications for patients with HIV

10:00 am 3.Cardiology
Fadi E. Shamoun, M.D.
11:00 am 4.HIV
John D. Zeuli, Pharm.D., R.Ph.
12:00 Noon Luncheon

Clinical Case Applications in Pharmacogenomics Part III
• Outline evidence‐based guidelines and literature to formulate patient‐specific medication regimen plans based on pharmacogenomic test results and other patient‐specific factors

• Identify variants and their impact on medications for the treatment of pain.


1:00 pm 5.Cancer/TPMT
Richard Weinshilboum, M.D.
2:00 pm 6.Pain
Wayne (Nick) T. Nicholson, M.D., Ph.D.

3:00 pm Break
Clinical Case Applications in Pharmacogenomics Part IV
• Describe current applications of pharmacogenomics in psychiatry practice
• Identify pharmaco-genes of clinical utility associated with pharmacogenomics testing for psychiatric medications
• Discuss impact on medication optimization through patient cases
3:15 pm 7. Transplant
Christopher B. Grilli, Pharm.D., R.Ph.
4:15 pm 8. Psych
Adrijana Kekic, Pharm.D.

5:15 pm Closing Comments and Adjourn

Learning Objectives:

Wayne T. Nicholson

Assistant Professor of Anesthesiology and Pharmacology
Mayo Clinic

Wayne (Nick) Nicholson, MD, PhD, is an Assistant Professor of Anesthesiology and Pharmacology in the College of Medicine. He is a currently a Consultant on the medical staff as a Clinical Pharmacologist in the Department of Anesthesiology. In addition to licensure in both medicine and pharmacy practice, he is credentialed by the American Board of Clinical Pharmacology and the Board of Pharmaceutical Specialties.

Presentation(s):

Send Email for Wayne Nicholson

Liewei Wang

Professor of Pharmacology Co-Director Mayo Pharmacogenomics Program
Mayo Clinic

Liewei Wang, MD, received her MD degree from FuDan University, Shanghai, China, followed by a PhD. degree from the Mayo Graduate School, with an emphasis on cancer biology and cancer pharmacology. Currently, she is a Professor of the Department of Molecular Pharmacology and Experimental Therapeutics at Mayo Clinic.

Dr. Wang has developed a research program with a focus on the use of high throughput genomic technology including array based and next generation sequencing methods, joined with a cell-based model system that consists of 300 lymphoblastoid cell lines, to study mechanisms of cancer biology and antineoplastic drug resistance, both chemotherapy and radiation therapy. In addition to her career-long involvement in pharmacogenomics, she also has extensive experience in functional genomics. She is involved in many clinical translational studies which help identify and understand biomarkers associated with clinical response to endocrine therapy and chemotherapy in breast cancer patients.

Dr. Wang is a member of several key programs at Mayo including: the Mayo-NIH Comprehensive Cancer Center (MCCC) and the Mayo Center for Individualized Medicine (CIM). She is also Co-Principal Investigator and the leader of the Functional Genomics Group for the Mayo-NIH Pharmacogenetics Research Network (PGRN) and the Co-Director for the Pharmacogenomics Program in the Mayo CIM.

Presentation(s):

Send Email for Liewei Wang


Assets

Pharmacogenomics: From Bench to Bedside (Part 2)
CME (AMA PRA Category 1 Credits™) 1.5; ACPE (UAN:0853-9999-17-047-L01-P) 1.5



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Pharmacogenomics: From Bench to Bedside (Part 2)
CME (AMA PRA Category 1 Credits™) 1.5; ACPE (UAN:0853-9999-17-047-L01-P) 1.5